

Vertebral Strength Gains From Small Rise in BMD

BY KERRI WACHTER
Senior Writer

NASHVILLE, TENN. — A little increase in bone mineral density associated with parathyroid hormone use appears to translate into greater vertebral strength, according to data presented at the annual meeting of the American Society for Bone and Mineral Research.

To assess changes in vertebral strength, the researchers used finite element analysis, a technique borrowed from engineering, where it is used to design bridges, skyscrapers, airplanes, and more, said Dennis M. Black, Ph.D., a professor of epidemiology at the University of California, San Francisco.

Starting with a quantitative CT (QCT) scan, the structure of interest is divided into

In engineering terms, strength means the applied force necessary for the structure to fail—the force necessary for the vertebra to fracture.

many finite elements—in this case voxels—each of which is assigned material properties based on the bone mineral density (BMD). Computer simulation is then used to apply a set of forces—in this case compressive force—to the model to

estimate the mechanical response. One of the responses of the most interest is strength, which in engineering terms means the applied force necessary for the structure to fail—in other words, the force necessary for the vertebra to fracture.

The researchers used the technique in a pilot study to assess vertebral strength changes, using data for 19 randomly selected women enrolled in the Parathyroid Hormone and Alendronate for Osteoporosis study. The postmenopausal women had all been randomized to receive 100 mcg of parathyroid hormone (1-84) daily for 1 year. QCT and dual x-ray absorptiometry (DXA) measurements were performed at baseline and at 1 year. The QCT data was used to look at changes in estimated vertebral strength using finite element analysis.

The average estimated compressive strength was 4,522 N. At 1 year the average estimated compressive strength was 5,715 N—a statistically significant increase in overall vertebral strength of 29%. While overall vertebral strength increased by 29%, overall BMD increased by only 6% based on DXA measurements.

The researchers were also able to virtually “peel away” the outer 2 mm of each vertebra (assumed to be cortical bone), in order to assess changes in the strength of trabecular bone. The increase in trabecular BMD was 29%, as measured by QCT. Trabecular bone accounted for 70% of the increase in total strength over the course of 1 year. At baseline, trabecular bone strength accounted for about half of total bone strength. “From this we inferred that the majority of the increase in strength is attributable to increases in tra-

becular strength,” Dr. Black explained.

The researchers also compared the increase in strength due to an average increase in bone density with the increase in strength due to a redistribution of bone density in the vertebra. To do this, the researchers assumed that the vertebra has a homogeneous density. So each element in the vertebra is assigned the same density—the average density for the vertebra. “So if we saw that the average density change leads to a strength change that is small, we

would then infer that some of the overall increase in strength is due to a redistribution of density,” said Dr. Black.

In fact, they found that the increase in average bone density accounted for most—but not all—of the increase in strength. “This suggests that not all of the increase in strength can be attributed to the average change in bone density,” he said.

Researchers had previously validated the technique for assessing vertebral compressive strength by comparing the re-

sults of compression tests on cadaveric vertebra (Bone 2003;33:744-50). The finite element measures of strength correlated well with the test results.

The study was funded in part by NPS Pharmaceuticals Inc., maker of Preos (recombinantly produced, full-length human PTH), which is under development. Dr. Black also receives consulting fees from NPS Pharmaceuticals and is speaker for Merck & Co. Inc., maker of Fosamax (alendronate). ■

MOBIC[®] (meloxicam)
the only once-daily
prescription NSAID
oral suspension
for treatment of the
signs and symptoms
of osteoarthritis,
rheumatoid arthritis, and
juvenile rheumatoid arthritis.



MOBIC is a nonsteroidal anti-inflammatory drug (NSAID) indicated to help relieve the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA) in adults. It is also indicated for the relief of the signs and symptoms of pauciarticular and polyarticular course juvenile rheumatoid arthritis (JRA) in patients 2 years of age and older. MOBIC is available in 7.5 mg and 15 mg tablets and a 7.5 mg/5 mL oral suspension. For the treatment of OA and RA the recommended starting and maintenance dose of MOBIC is 7.5 mg once daily. Some adult patients may receive additional benefit by increasing the dose up to a maximum of 15 mg once daily. For the treatment of JRA, the recommended starting and maintenance dose of MOBIC oral suspension is 0.125 mg/kg, once daily, up to a maximum of 7.5 mg per day.

Carefully consider the potential benefits and risks of MOBIC and other treatment options before deciding to use MOBIC. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.

NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.

MOBIC is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.

NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events.

MOBIC is contraindicated in patients with known hypersensitivity to meloxicam. It should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients.

Please see following pages for Brief Summary of full Prescribing Information, including boxed WARNING.

Serious skin side effects can occur without warning, which may result in hospitalization and even death. Patients should be advised that if they develop any type of rash they should stop the drug immediately and contact their physicians as soon as possible.

Fluid retention and edema have been observed in some patients taking NSAIDs. Patients should be advised to promptly report signs or symptoms of unexplained weight gain or edema to their physicians. MOBIC should be used with caution in patients with fluid retention or heart failure.

NSAIDs, including MOBIC, can lead to onset of new hypertension or worsening of pre-existing hypertension.

Health care providers should refer to the full Prescribing Information before prescribing MOBIC to pregnant women. However, MOBIC should be avoided in late pregnancy because it may cause premature closure of the ductus arteriosus.

Patients should be informed of the warning signs and symptoms of hepatotoxicity.

NSAIDs may adversely impact the kidneys, resulting in renal papillary necrosis or other renal injury or overt renal decompensation. Patients should be monitored closely.

In clinical trials in adults with OA and RA, the most common side effects were diarrhea, indigestion, headache and flu-like symptoms. In clinical trials in children with JRA, the most common side effects were abdominal pain, vomiting, diarrhea, headache and pyrexia.

Coming Soon

mobic[®] (meloxicam)
tablets/oral suspension

MB-10808A